Taipei Medical University

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Wang TL
------>authors3_c=None
------>paper_class1=1
------>Impact_Factor=None
------>paper_class3=2
------>paper_class2=1
------>vol=37
------>confirm_bywho=soulchin
------>insert_bywho=m002183
------>Jurnal_Rank=None
------>authors4_c=None
------>comm_author=
------>patent_EDate=None
------>authors5_c=None
------>publish_day=None
------>paper_class2Letter=None
------>page2=449
------>medlineContent=
------>unit=E0110
------>insert_date=20040419
------>iam=1
------>update_date=None
------>author=???
------>change_event=5
------>ISSN=None
------>authors_c=None
------>score=500
------>journal_name=Ann Emerg Med
------>paper_name=Intravenous morphine reduces plasma endothelin 1 concentration through activation of neutral endopeptidase 24.11 in patients with myocardial infarction.
------>confirm_date=20040419
------>tch_id=092079
------>pmid=11326179
------>page1=445
------>fullAbstract=STUDY OBJECTIVE: Morphine has multiple cardiovascular effects, but its action on hydrolysis of endothelin 1 (ET-1) has not been investigated. METHODS: We measured plasma levels of ET-1, C-terminal degradation products of ET-1, and neutral endopeptidase 24.11 (NEP) in 68 patients with acute Q-wave myocardial infarction and 29 control subjects. All the patients underwent blood sampling at initial presentation and 10 minutes later. Thirty-six of those with Q-wave myocardial infarction intravenously received 3 mg of morphine immediately after the first sampling (group 1), and the other 32 received the same after the second sampling (group 2). Twenty-four of the control subjects (group 3) were randomized to the protocol of group 1, and the remaining 5 subjects (group 4) were randomized to the protocol of group 2. RESULTS: The plasma ET-1 levels were significantly higher in groups 1 and 2 than in groups 3 and 4 (control groups). In group 1, the ET-1 level decreased significantly at second blood samplings (2.5+/-0.4 pmol/L versus 1.7+/-0.6 pmol/L, P <.001), whereas there were no definite changes of ET-1 levels in group 2 (2.5+/-0.5 pmol/L versus 2.6+/-0.6 pmol/L, P =not significant). However, the C-terminal degradation products increased significantly at second blood samplings in group 1 (0.8+/-0.2 pmol/L versus 1.3+/-0.4 pmol/L, P <.001), whereas there were no definite changes in group 2 (0.9+/-0.3 pmol/L versus 0.9+/-0.4 pmol/L, P =not significant). There was no significant difference in baseline NEP activities between groups 1 and 2 (5.02+/-1.30 nmol/mg protein versus 5.06+/-1.48 nmol/mg protein, P =not significant). However, the NEP activities at second blood samplings declined significantly in group 1 (9.76+/-1.76 nmol/mg protein, P <.001 versus baseline), whereas no definite changes were observed in group 2 (5.09+/-1.62 nmol/mg protein, P =not significant versus baseline). CONCLUSION: Intravenous morphine may increase NEP activities to accentuate hydrolysis of ET-1.
------>tmu_sno=None
------>sno=8526
------>authors2=Chang H
------>authors3=
------>authors4=
------>authors5=
------>authors6=
------>authors6_c=None
------>authors=Wang TL
------>delete_flag=0
------>SCI_JNo=None
------>authors2_c=None
------>publish_area=None
------>updateTitle=Intravenous morphine reduces plasma endothelin 1 concentration through activation of neutral endopeptidase 24.11 in patients with myocardial infarction.
------>language=2
------>check_flag=None
------>submit_date=None
------>country=None
------>no=
------>patent_SDate=None
------>update_bywho=None
------>publish_year=2001
------>submit_flag=None
------>publish_month=None
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z